Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors - Wikidata - wikimedia - TriplyDB

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

http://www.wikidata.org/entity/Q33621243

about

Targeting Cell Survival Proteins for Cancer Cell Death Other targeted drugs in melanoma Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation.Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions Induced protein degradation: an emerging drug discovery paradigm.Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78.The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas.Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.Inflammatory stress and sarcomagenesis: a vicious interplay.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.GIST treatment options after tyrosine kinase inhibitors.Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.Current research and treatment for gastrointestinal stromal tumors.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.New targets and therapies for gastrointestinal stromal tumors.Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening.Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma.Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.

P2860

Q26765447-B5BAED9B-F281-45C1-875D-D6CE34E4225A Q26775594-B92C43B2-B5F4-448B-948D-DC487D478DAC Q26799387-E9F8ABFC-4FC7-49F1-8EEA-0F33A74B8A2B Q27692108-11989BBA-BDD7-4A10-BA63-2F33EC40C6EF Q33410655-52234D78-CC30-420C-9317-4ED642583140 Q33706374-2AFA63B6-22CE-41C9-B396-44C084FCD06B Q34164027-F7968339-70FA-49FF-9035-E9276EF70AA2 Q34545841-54C1FDAD-2D22-4F37-ACA4-CEADB12A8C1F Q34629026-DAD06F60-5B28-49B0-8369-7605F27C37F0 Q34957090-AE879CBC-44A6-4AFE-A48D-83D05FBBE23E Q35044980-0465D950-59B6-4D8F-86A8-4DDBD299D7D1 Q35098333-4008FBBE-919E-4D76-8EC1-4CA8C2156077 Q35111102-91026B15-2DB1-4ED9-A890-BA6678A576CF Q35336213-912AB5EC-EC30-46BE-847E-E0389C2BD858 Q36125976-D3E3B9F0-8B87-46BC-81E8-FD2D93B2F9C4 Q36540475-668A3292-4C78-40B0-AD85-6787F6A1115E Q37040615-A8E04497-2991-46BB-951E-1E91BF13E86C Q37198085-D873B18A-42D8-4F86-9A02-E78A8A92CCD4 Q37204596-2CBC6AED-B138-4F90-AAC2-3502AB19B494 Q37220191-70C6D3A4-155B-49EC-A239-01C5E52B41E7 Q37245887-5A985D0C-AFED-491C-9ACD-AE6C992499AC Q37378867-B75E5D52-1041-4B4B-B526-B9116E6B0AF7 Q38112821-D523ECC8-CA0B-43F1-8873-E945E4CD55C9 Q38222205-6630AD31-6CA3-43FA-BEAC-4701C58515F3 Q38502737-F186A4A0-6B0A-4685-8D2E-F696AA9B1F0E Q38527941-2C41D60B-7AB9-4974-B77A-3329A652B697 Q38668524-48A2C346-98B6-4B5D-BF6E-52A6BF907B19 Q39263075-ABBDF67E-63C1-4AD1-BF49-343D8EBF0737 Q39288497-03009390-1DD6-47C0-89EE-D7831FA622C1 Q40182987-C06775AC-2173-46E4-B012-952A84E44966 Q41026661-9F0DF188-B5FB-4B47-8A7E-333C282C7724 Q41127921-BEDCF7E3-8237-4EF8-A823-B690AABF54AE Q42337115-8C4332D9-D0F4-4E77-A737-9D04456C9CDE Q47097647-1357A48D-2763-4359-878E-9D5AA385E3DD Q47432725-CED8DD95-3747-434A-994D-A71C1F3D9712 Q47694405-CE49A683-AB73-4192-89E8-A454E6046C0B Q51598140-677401CC-4BF2-44DD-88C0-EFEBCC3D6A86 Q54355782-B4123ACC-CD13-4F5C-9149-77B2BCB23E3C Q54863183-1F5FD39E-4EE5-476A-AE9A-C394EE59CD91

P2860

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

http://www.wikidata.org/entity/Q33621243

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@ast

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@en

type

label

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@ast

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@en

prefLabel

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@ast

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@en

P1433

Q33621243-AC6680BC-DD0C-4B3B-8C1B-C2AA58BEBF36

P1476

Q33621243-39C7CEAB-9ADE-41A4-9028-CD2789D60FBE

P2093

Q33621243-03116D2C-B8ED-45E0-8165-8113D9795725

Q33621243-541DD786-66B8-42D9-9160-3DB90D19EE59

Q33621243-56F9B2D1-AC08-4078-A9AA-45DB662738B0

Q33621243-8E1EA53D-6D29-4637-A508-EE93E7440E43

Q33621243-BE12E4F2-408E-4227-9DA0-8D9E92525AEF

Q33621243-D03251E2-C25C-42EA-AAB5-884DC7C13D41

Q33621243-D5CD650B-A423-477B-BF5E-969206D043E5

Q33621243-E4982EF9-DAD9-4E2E-91BE-A7BF3D0092A1

P2860

Q33621243-00193505-1256-41FC-95A0-FF6A54464688

Q33621243-02F06203-B601-4FAB-85B0-F442CEA5DA40

Q33621243-1855394A-C17B-469C-9AF7-440A5608C8D6

Q33621243-26A638EA-9AB8-4DDD-8922-C75B239855B4

Q33621243-2C1EBC39-24A5-4CB4-ABB9-0FA3A4F09D97

Q33621243-2E9201CC-C9C8-417F-AA2D-03627141383B

Q33621243-3183A407-0DFF-456C-832F-45FD0E7015FC

Q33621243-3F823060-DE45-476B-9A4D-7CA9EC120E2E

Q33621243-4A95D563-D873-49D1-9F25-4CC126419938

Q33621243-7BE3B4BE-EB6E-483A-9447-8DC4AFCFDEBA

P304

Q33621243-C948FA8B-182D-417F-B665-55058B0CCD9E

P31

Q33621243-3B2F08B1-B6B5-4C76-9537-11B3A38CA4BA

P356

Q33621243-96CB2240-88EC-47BB-A30D-6C5C97A6385E

P433

Q33621243-2959CFA0-4A6F-4254-8F22-510AF9993B1C

P478

Q33621243-FA9F30ED-D2EF-4DBF-B73C-AE739948E59F

P577

Q33621243-5C0B99BB-802C-4543-9A85-4909370F258E

P5875

Q33621243-CA9652CA-D9F7-4C90-8313-6169E9D7D0F5

P698

Q33621243-A3BDC9B5-E110-4970-B363-756433827CED

P921

Q33621243-377A377E-3DC5-419F-BABE-0349C3872B79

P932

Q33621243-7BA70BA1-437B-4683-8F24-5893E52F7873

P356

P1433

Annals of Oncology

P1476

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

@en

P2093

C R Antonescu

http://www.w3.org/2001/XMLSchema#string

D R D'Adamo

http://www.w3.org/2001/XMLSchema#string

G K Schwartz

http://www.w3.org/2001/XMLSchema#string

M A Dickson

http://www.w3.org/2001/XMLSchema#string

M L Keohan

http://www.w3.org/2001/XMLSchema#string

R G Maki

http://www.w3.org/2001/XMLSchema#string

S H Okuno

http://www.w3.org/2001/XMLSchema#string

T J Akhurst

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Gastrointestinal stromal tumour.

The lessons of GIST--PET and PET/CT: a new paradigm for imaging.

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.

BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

P304

252-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS275

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230684624

http://www.w3.org/2001/XMLSchema#string

P698

22898035

http://www.w3.org/2001/XMLSchema#string

P921

P932

4023320

http://www.w3.org/2001/XMLSchema#string